Related Experiment Video
Updated: May 22, 2026
Assessing Iron Deposition in the Brains of 5xFAD Mice by Perls'/DAB Staining
Published on: May 23, 2025
Deferoxamine attenuates iron-induced long-term neurotoxicity in rats with traumatic brain injury
1Department of Neurosurgery, Southwest Hospital, Third Military Medical University, Gaotanyan 30, Chongqing 400038, People's Republic of China.
Abstract:
This study investigated whether deferoxamine (DFO), an iron chelator attenuates iron-induced toxicity in rats with traumatic brain injury. In this study, three groups of Sprague-Dawley rats (sham, injury and DFO groups) were examined. Rats were killed on day 28 after Morris water maze testing and brains perfused for either non-heme brain binding or hemosiderin staining. Western blotting was used to measure protein levels of ferritin, transferrin and transient receptor potential canonical channel 6 (TRPC6). In TBI rats, there was a significant increase in brain iron on day 28, ferritin L, ferritin H, transferrin and TRPC6 levels were all significantly elevated post-TB1. There were also deficits in spatial learning and memory; however, DFO administration attenuated these effects in TBI rats supporting the notion that DFO may reduce brain injury accentuated by iron overload.
Insights
Deferoxamine (DFO), an iron chelator, reduced iron-induced toxicity and improved spatial learning and memory in rats with traumatic brain injury (TBI). DFO treatment attenuated elevated brain iron and related protein levels post-TBI.
Area of Science:
- Neuroscience
- Biochemistry
- Pharmacology
Background:
- Traumatic brain injury (TBI) can lead to increased iron accumulation in the brain.
- Elevated iron levels are associated with neurotoxicity and cognitive deficits following TBI.
- Iron dysregulation plays a critical role in secondary injury mechanisms.
Purpose of the Study:
- To investigate the neuroprotective effects of deferoxamine (DFO) in a rat model of TBI.
- To determine if DFO, an iron chelator, can attenuate iron-induced toxicity and cognitive impairments post-TBI.
- To examine the impact of DFO on brain iron levels and associated protein expression.
Main Methods:
- Establishment of a TBI model in Sprague-Dawley rats with sham, injury, and DFO-treated groups.
- Assessment of spatial learning and memory using the Morris water maze test on day 28 post-injury.
- Quantification of non-heme iron and hemosiderin in brain tissue.
- Measurement of protein levels for ferritin (L and H subunits), transferrin, and transient receptor potential canonical channel 6 (TRPC6) via Western blotting.
Main Results:
- TBI rats exhibited significantly increased brain iron levels by day 28 post-injury.
- Elevated expression of ferritin L, ferritin H, transferrin, and TRPC6 was observed in TBI rats.
- Significant deficits in spatial learning and memory were evident in TBI rats.
- DFO administration significantly attenuated the cognitive deficits and molecular changes in TBI rats.
Conclusions:
- Iron overload contributes significantly to brain injury and cognitive dysfunction following TBI.
- Deferoxamine (DFO) demonstrates neuroprotective effects by chelating excess iron.
- DFO treatment may be a viable therapeutic strategy to mitigate TBI-induced neurotoxicity and cognitive impairments.
